Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282022 · ClinicalTrials.gov registry record · Phase 2
VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer
A Phase 2 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT00282022 is a Phase 2 study that has completed, run by Vion Pharmaceuticals. The registered enrollment target is 87 participants.
The verdict
NCT00282022, a Phase 2 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well VNP40101M works in treating patients with recurrent or refractory locally advanced or metastatic small cell lung cancer.
Interventions
- DRUG laromustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282022
The ClinicalTrials.gov registry entry for NCT00282022 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vion Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which laromustine is the first listed.
NCT00282022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282022 about?
NCT00282022 is a clinical study titled "VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well VNP40101M works in treating patients with recurrent or refractory loca...
What is the current status of trial NCT00282022?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2005-09.
What interventions are being tested in trial NCT00282022?
The interventions under investigation include: laromustine (DRUG).
Who is sponsoring clinical trial NCT00282022?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.